Press "Enter" to skip to content

Lyme Disease Vaccine: Pfizer Launches Phase 3 Trial Targeting Kids, Adults

By Megan Redshaw

Pfizer on Monday said it launched the final phase of testing for an experimental vaccine to prevent Lyme disease.

The company plans to create a seasonal vaccine that people age 5 and older can get during the months when ticks are most active.

If approved, the vaccine could be the first human vaccine available for Lyme disease in the U.S. in more than two decades after LYMERix, manufactured by GlaxoSmithKline, was withdrawn from the market in 2002, due to lawsuits, safety concerns and dwindling sales.

According to a press release, Pfizer and French partner Valneva are enlisting 6,000 participants ages 5 and older for a late-stage clinical trial that will test the vaccine, VLA15, against the tick-borne illness…

Read More Here

News PDF Archives – Jellyfish.NEWS

Breaking News: